In a recent video from one of our investors, Calculus Capital, David Venables discusses Synpromics’ disruptive technology and how it enables the control of genetic ‘switches’ aiding the development of cures for a wide range of genetic diseases. The investment from Calculus Capital has allowed Synpromics to expand and provided further funding for R&D, driving deal value growth.

Alexander Crawford explains why Calculus Capital invests in Synpromics and the potential for the future as gene therapies featuring Synpromics’ transformative technology come to market.

For further information on Calculus Capital and our other investors, visit our Investors page.